Small molecule TK inhibitors targeting CD115 have been shown efficacious in inhibiting cancer-induced osteolysis [46], [51]–[53], although it remained unclear whether this was due to an effect on tumor cells, on mouse osteoclasts, or even on another TKR - since small molecule TK inhibitors generally lack selectivity. This evidence concerns the gene TKTL1 and cancer.